EnvisionRx Continues its Clinical Prominence as One of the Nation’s Best at Drug Therapy
December 11 2017 - 3:17PM
Business Wire
One of only four pharmacy benefit managers to
hold URAC accreditation for Drug Therapy Management, EnvisionRx
continues to lower payer costs with proven analytics and patient
engagement
Excellence in Drug Therapy Management is
crucial to helping patients adhere to medication therapies, leading
to healthier outcomes and lower out-of-pocket costs
EnvisionRx, a pharmacy benefit manager (PBM)
and division of EnvisionRxOptions, a wholly owned subsidiary
of Rite Aid Corporation, today announced it has achieved
renewal of the Drug Therapy Management (DTM) accreditation by
URAC. This accreditation recognizes healthcare organizations that
provide innovative ways to manage and incorporate DTM into their
clinical care management programs. EnvisionRx is one of only four
organizations to accomplish this accreditation, which Envision has
held since 2007.
URAC is a third-party accrediting organization with a mission of
promoting continuous improvement in the quality and efficiency of
healthcare management. The accreditation process demonstrates a
commitment to quality services and serves as a framework to improve
business processes through benchmarking organizations against
nationally recognized standards. URAC’s DTM accreditation standards
assess a range of professional activities, including formulating
medication treatment plans, monitoring efficacy and safety of
medication therapy and enhancing medication adherence through
patient empowerment and education.
“EnvisionRx is part of an elite group of just four organizations
nationwide that meet URAC’s rigorous standards for quality and
accountability in Drug Therapy Management,” said Frank Sheehy, CEO
of EnvisionRxOptions. “EnvisionRx provides extensive clinical
options that better manage increasingly complex conditions and make
medications more affordable for both patients and plan sponsors. By
integrating our PBM services with our URAC-accredited specialty
pharmacy, EnvisionPharmacies, we are better able to manage the
necessary drug therapies for costly, chronic conditions, and
through our EnvisionCare model, we optimize all aspects of the
pharmacy care experience to consistently achieve better patient and
plan outcomes.”
Increase in Chronic Conditions and Costly Specialty
Medications Drive Need for Drug Therapy Programs
According to the Centers for Disease Control and Prevention
(CDC), half of U.S. adults have at least one chronic disease—heart
disease, stroke, cancer, type 2 diabetes, obesity, and
arthritis—and one in four have more than two of these conditions.
Complex in nature, these chronic conditions are costly and a top
cause of death.1 Many chronic conditions require expensive
specialty medications that can have severe initial side effects and
often increase the patient’s cost share, and dramatically increase
the rate at which patients abandon their prescribed therapies.
Drug Therapy Management programs play an important role in the
proper management of chronic conditions, leading to better disease
control, reduction in disease-related complications, and overall
improvement in health. Additionally, DTM programs integrated with a
specialty pharmacy help improve patient adherence to prescribed
drug therapy, reduce medication and healthcare costs, and ensure
safe and effective pharmacy care.
“By meeting rigorous quality standards and measures, URAC has
accredited EnvisionRx as a recognition of its ability to adhere to
the best practices related to factors such as coordinated care,
counseling and education, and consumer protection,” said URAC
President and CEO Kylanne Green.
The URAC DTM accreditation ensures that an organizations’ DTM
program achieves the ability to drive appropriate therapeutic
outcomes for consumers and reduce adverse events; promotes
rational, clinically appropriate, safe and cost-effective DTM
through evidence-based medicine; encourages communication about
medication use; and creates processes for the measurement of DTM
outcomes and quality improvement.
“We take our role of ensuring safe and effective pharmacy care
very seriously,” said Sheehy. “It is our job to make sure that
patients in our care understand their medications and ensure
appropriate use. This nod of accreditation by URAC is just another
affirmation of our company’s commitment to the overall improvement
of healthcare.”
As a healthcare company that owns all of the pieces needed to
fully optimize the pharmacy care experience, EnvisionRxOptions also
holds URAC accreditations for its pharmacy benefit management
division and mail order and specialty pharmacies.
About EnvisionRx
EnvisionRx is a division of EnvisionRxOptions, a healthcare
company with a visibly different approach to managing pharmacy
benefits and a wholly owned subsidiary of Rite Aid. EnvisionRx
offers pharmacy benefit management (PBM) services to employers and
health plans of all sizes, providing more affordable and effective
prescription drug coverage for members. Through its proprietary
EnvisionCare model, EnvisionRx optimizes the pharmacy care
experience to consistently achieve better patient and plan
outcomes. EnvisionRx’s flexible, transparent and customizable
services offer payers a variety of options, including traditional
and pass-through pricing, unique network and formulary design, and
specialty pharmacy care. For more information, visit
envisionrx.com.
About URAC
Founded in 1990, URAC is the independent leader in promoting
healthcare quality through accreditation, certification and
measurement. URAC is a nonprofit organization developing
evidence-based measures and standards through inclusive engagement
with a range of stakeholders committed to improving the quality of
healthcare. Our portfolio of accreditation and certification
programs span the healthcare industry, addressing healthcare
management, healthcare operations, health plans, pharmacies,
telehealth providers, physician practices, and more. URAC
accreditation is a symbol of excellence for organizations to
showcase their validated commitment to quality and accountability.
For more information, visit www.urac.org
1 Center for Disease Control and Prevention, 2017. Chronic
Diseases: The Leading Causes of Death and Disability in the United
States. Chronic Disease Overview. Retrieved from
https://www.cdc.gov/chronicdisease/overview/index.htm#ref1
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171211006117/en/
EnvisionRxOptionsBobby Creek,
813-690-8503bcreek@envisionrx.com
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rite Aid (NYSE:RAD)
Historical Stock Chart
From Apr 2023 to Apr 2024